

# Giovanni Storto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5347964/publications.pdf>

Version: 2024-02-01

81  
papers

1,589  
citations

279487

23  
h-index

360668

35  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2377  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer. <i>Cancers</i> , 2022, 14, 2958.	1.7	4
2	Assessment of Residual Radioactivity by a Comprehensive Wireless, Wearable Device in Thyroid Cancer Patients Undergoing Radionuclide Therapy and Comparison With the Results of a Home Device: A Feasibility Study. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2021, 9, 1-6.	2.2	2
3	Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2871-2882.	3.3	11
4	F-18 FDG PET/CT and F-18 FLT PET/CT as predictors of outcome in patients with multiple myeloma. A pilot study. <i>European Journal of Radiology</i> , 2021, 136, 109564.	1.2	2
5	A mass transfer model for computational prediction of proliferation and therapy outcome of non-Hodgkin lymphoma. <i>International Communications in Heat and Mass Transfer</i> , 2021, 125, 105332.	2.9	3
6	Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer. <i>Future Science OA</i> , 2021, 7, FSO719.	0.9	6
7	TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas. <i>Molecular Oncology</i> , 2020, 14, 3030-3047.	2.1	19
8	<p>Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7605-7614.	1.0	2
9	Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9-13.	1.0	10
10	Adapting and Surviving: Intra and Extra-Cellular Remodeling in Drug-Resistant Gastric Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3736.	1.8	51
11	Exploring the Molecular Crosstalk between Pancreatic Bud and Mesenchyme in Embryogenesis: Novel Signals Involved. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4900.	1.8	3
12	BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. <i>Cancers</i> , 2019, 11, 1388.	1.7	73
13	Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why. <i>Tumori</i> , 2019, 105, 367-377.	0.6	17
14	Sex and gender issues in cardiotoxicity: Are we ready for gynecardiooncology?. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 1018.	1.4	0
15	Colorectal cancer: Parametric evaluation of morphological, functional and molecular tomographic imaging. <i>World Journal of Gastroenterology</i> , 2019, 25, 5233-5256.	1.4	22
16	Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells. <i>Tumor Biology</i> , 2018, 40, 101042831877095.	0.8	7
17	Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1908-1914.	3.3	12
18	F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer. <i>European Journal of Radiology</i> , 2017, 93, 107-113.	1.2	18

#	ARTICLE	IF	CITATIONS
19	Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy. <i>Medicine (United States)</i> , 2017, 96, e8344.	0.4	12
20	The current and evolving role of FDG PET/CT in personalized iodine-131 therapy of differentiated thyroid cancer. <i>Clinical and Translational Imaging</i> , 2017, 5, 533-544.	1.1	4
21	Therapeutic Strategies in HCC: Radiation Modalities. <i>BioMed Research International</i> , 2016, 2016, 1-11.	0.9	21
22	The value of a tailored evaluation before cancer therapy: is there a way to predict the aftermath of radiotherapy in breast cancer patients? Preliminary data of an observational study. <i>Annals of Oncology</i> , 2016, 27, iv120.	0.6	0
23	Letter by Gallucci and Storto Regarding Article, "Vascular Toxicities of Cancer Therapies: The Old and the New" An Evolving Avenue. <i>Circulation</i> , 2016, 134, e464-e465.	1.6	0
24	The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	20
25	Gynecologic history: What is the aftermath of a complicated pregnancy?. <i>International Journal of Cardiology</i> , 2016, 222, 990-991.	0.8	0
26	TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells. <i>Endocrine-Related Cancer</i> , 2016, 23, 699-709.	1.6	24
27	Diffusion volume (DV) measurement in endometrial and cervical cancer: A new MRI parameter in the evaluation of the tumor grading and the risk classification. <i>European Journal of Radiology</i> , 2016, 85, 113-124.	1.2	32
28	18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. <i>Leukemia</i> , 2016, 30, 417-422.	3.3	120
29	Evaluation of Glucose Uptake in Normal and Cancer Cell Lines by Positron Emission Tomography. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00021.	0.7	21
30	Achievement of European Standards by CROB-IRCCS. <i>Tumori</i> , 2015, 101, S47-S50.	0.6	2
31	[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients. <i>Radiology and Oncology</i> , 2015, 49, 320-326.	0.6	23
32	Quantitative Assessment of Myocardial Blood Flow with SPECT. <i>Progress in Cardiovascular Diseases</i> , 2015, 57, 607-614.	1.6	28
33	Prognostic Role of 18F-FDG PET/CT in the Postoperative Evaluation of Differentiated Thyroid Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2015, 40, 111-115.	0.7	25
34	Non-invasive diagnostic imaging of colorectal liver metastases. <i>World Journal of Radiology</i> , 2015, 7, 157.	0.5	29
35	Evaluation of Glucose Uptake in Normal and Cancer Cell Lines by Positron Emission Tomography. <i>Molecular Imaging</i> , 2015, 14, 490-8.	0.7	6
36	The intriguing issue of genetic predisposition and the importance of identification of pre-clinical markers of endothelial damage in radiotherapy-induced cardiotoxicity. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 233-233.	0.5	4

#	ARTICLE	IF	CITATIONS
37	F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2014, 92, 382-389.	1.1	67
38	Critical dose and toxicity index of organs at risk in radiotherapy: Analyzing the calculated effects of modified dose fractionation in non-small cell lung cancer. <i>Medical Dosimetry</i> , 2014, 39, 23-30.	0.4	2
39	Clinical radiobiology of glioblastoma multiforme. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 925-932.	1.0	45
40	Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain. <i>Journal of Bone and Mineral Metabolism</i> , 2014, 32, 434-440.	1.3	14
41	MRI findings of a remote and isolated vaginal metastasis revealing an adenocarcinoma of the mid-sigmoid colon. <i>Polski Przegląd Radiologii I Medycyny Nuklearnej</i> , 2014, 79, 33-35.	1.0	6
42	Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma. <i>Clinical and Translational Oncology</i> , 2013, 15, 919-924.	1.2	7
43	F-18 FDG PET/CT in the assessment of patients with unexplained CEA rise after surgical curative resection for colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2013, 28, 1699-1705.	1.0	9
44	Impact of 18F-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP. <i>Nuclear Medicine and Biology</i> , 2013, 40, 518-523.	0.3	9
45	Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?. <i>Endocrine</i> , 2013, 44, 426-433.	1.1	36
46	Local tumor control probability to evaluate an applicator-guided volumetric modulated arc therapy solution as alternative of 3D brachytherapy for the treatment of the vaginal vault in patients affected by gynecological cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2013, 14, 146-157.	0.8	7
47	Modelling the correlation between EGFR expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFR inhibitors. <i>Theoretical Biology and Medical Modelling</i> , 2012, 9, 23.	2.1	13
48	Correlation between egfr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. <i>Radiation Oncology</i> , 2012, 7, 143.	1.2	29
49	Incremental prognostic value of coronary flow reserve assessed with single-photon emission computed tomography. <i>Journal of Nuclear Cardiology</i> , 2011, 18, 612-619.	1.4	38
50	Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90. <i>Applied Radiation and Isotopes</i> , 2011, 69, 52-55.	0.7	6
51	Colorectal cancer and 18FDG-PET/CT: What about adding the T to the N parameter in loco-regional staging?. <i>World Journal of Gastroenterology</i> , 2011, 17, 1427.	1.4	29
52	Noninvasive quantification of coronary endothelial function by SPECT imaging in children with a history of Kawasaki disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2249-2255.	3.3	15
53	Assessment of metabolic activity by PET/CT with F-18 FDG in patients with T-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 195-197.	1.2	15
54	Assessment of Metabolic Response to Radioimmunotherapy with <sup>90</sup> Y-ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Radiology</i> , 2010, 254, 245-252.	3.6	29

#	ARTICLE	IF	CITATIONS
55	The Clinical Impact of a Cardiac Follow-up in Breast Cancer Survivors: An Observational Study. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 1221-1227.	1.0	8
56	Assessment of the arterial input function for estimation of coronary flow reserve by single photon emission computed tomography: comparison of two different approaches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 2034-2041.	3.3	15
57	Cardiac performance during exercise in hypertensive patients without ventricular hypertrophy. <i>European Journal of Clinical Investigation</i> , 2009, 39, 664-670.	1.7	4
58	Radionuclide Therapy. <i>Cancer Metastasis - Biology and Treatment</i> , 2009, , 321-341.	0.1	2
59	Postsurgical diagnostic evaluation of patients with differentiated thyroid carcinoma: comparison of ultrasound, iodine-131 scintigraphy and PET with fluorine-18 fluorodeoxyglucose. <i>Radiologia Medica</i> , 2008, 113, 278-288.	4.7	5
60	Assessment of coronary flow reserve using single photon emission computed tomography with technetium 99m-labeled tracers. <i>Journal of Nuclear Cardiology</i> , 2008, 15, 456-465.	1.4	32
61	Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 352-359.	1.8	3
62	Estimation of coronary flow reserve by sestamibi imaging in type 2 diabetic patients with normal coronary arteries. <i>Journal of Nuclear Cardiology</i> , 2007, 14, 194-199.	1.4	24
63	Assessment of coronary flow reserve by sestamibi imaging in patients with typical chest pain and normal coronary arteries. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1156-1161.	3.3	18
64	Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. <i>Bone</i> , 2006, 39, 35-41.	1.4	68
65	Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 179-183.	3.3	24
66	Relations of left ventricular mass and systolic function to endothelial function and coronary flow reserve in healthy, new discovered hypertensive subjects. <i>Journal of Human Hypertension</i> , 2005, 19, 941-950.	1.0	19
67	Relation of Brachial Artery Flow-Mediated Vasodilation to Significant Coronary Artery Disease in Patients With Peripheral Arterial Disease. <i>American Journal of Cardiology</i> , 2005, 96, 1337-1341.	0.7	53
68	Influence of risk factors on coronary flow reserve in patients with 1-vessel coronary artery disease. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1438-43.	2.8	10
69	Relationship between brachial artery flow-mediated dilation and coronary flow reserve in patients with peripheral artery disease. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1997-2002.	2.8	39
70	Relation between wall thickening on gated perfusion SPECT and functional recovery after coronary revascularization in patients with previous myocardial infarction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1599-1605.	3.3	13
71	Early and late effects of coronary artery bypass grafting on cardiac haemodynamics during daily physical activities in patients with coronary artery disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 852-856.	3.3	4
72	Estimation of coronary flow reserve by Tc-99m sestamibi imaging in patients with coronary artery disease: Comparison with the results of intracoronary Doppler technique. <i>Journal of Nuclear Cardiology</i> , 2004, 11, 682-688.	1.4	48

#	ARTICLE	IF	CITATIONS
73	Hemodynamic effects of isometric exercise in hypertrophic cardiomyopathy: Comparison with normal subjects. <i>Journal of Nuclear Cardiology</i> , 2003, 10, 154-160.	1.4	9
74	Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2002, 40, 278-284.	1.2	80
75	Comparison of hemodynamic adaptation to orthostatic stress in patients with hypertrophic cardiomyopathy with or without syncope and in vasovagal syncope. <i>American Journal of Cardiology</i> , 2002, 89, 1405-1410.	0.7	17
76	Prediction of long-term effects of revascularization on regional and global left ventricular function by dobutamine echocardiography and rest Tl-201 imaging alone and in combination in patients with chronic coronary artery disease. <i>Journal of Nuclear Cardiology</i> , 2002, 9, 174-182.	1.4	17
77	Biokinetics of a F(ab $\epsilon$ 2)Iodine-131 Labeled Antigen Binding Construct (MAb 35) Directed Against CEA in Patients with Colorectal Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2001, 16, 371-379.	0.7	9
78	Diagnostic accuracy of low-dose dobutamine echocardiography in predicting post-revascularisation recovery of function in patients with chronic coronary artery disease: relationship to thallium-201 uptake. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1616-1623.	2.2	11
79	Radionuclide monitoring of left ventricular function. <i>Journal of Nuclear Cardiology</i> , 2001, 8, 606-615.	1.4	4
80	Prediction of improvement in global left ventricular function in patients with chronic coronary artery disease and impaired left ventricular function: rest thallium-201 SPET versus low-dose dobutamine echocardiography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1740-1746.	2.2	14
81	Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension. <i>Journal of Hypertension</i> , 1999, 17, 1759-1766.	0.3	29